Phase 1 data reinforce clinical profile of epacadostat in combination with Keytruda®
Incyte announced the European Society for Medical Oncology has published updated data from the Phase 1 portion of the ECHO-202 trial evaluating safety and efficacy of epacadostat in combination with Keytruda® (pembrolizumab), Merck’s anti-PD-1 therapy. September 28, 2016